ABT Abbott Labs: רווח נקי למניה ב-12 החודשים האחרונים

Stable demand for infant formula and glucose sensors guarantees a predictable cash flow for Abbott Laboratories (ABT). Net income per share over the last 12 months visualizes this resilience, where 2.71 serves as the current parameter value. Profit growth is based on R&D leadership and the development of pacemakers, as well as the integration of digital services and wearable devices into a single health ecosystem.

Stable staffing and the retention of leading engineers at Abbott Laboratories (ABT) ensure technological continuity, which translates directly into sustainable profit growth. By analyzing the annual earnings per share trend, an investor sees the net profit over 12 months distributed across the total share issuance, allowing them to filter out market noise and assess the real efficiency of the business.